Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
Revolution Medicines (Nasdaq: RVMD), a clinical-stage oncology company, will report its financial results for the third quarter of 2024 on November 6, 2024, after market close.
A webcast hosted by senior management will follow at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the results and provide a corporate update. The webcast will be available live and as an archived replay on the company's website for at least 14 days.
Revolution Medicines (Nasdaq: RVMD), un'azienda oncologica in fase clinica, presenterà i suoi risultati finanziari per il terzo trimestre del 2024 il 6 novembre 2024, dopo la chiusura del mercato.
Un webcast ospitato dai dirigenti senior seguirà alle 16:30 ora orientale (13:30 ora del Pacifico) per discutere i risultati e fornire un aggiornamento aziendale. Il webcast sarà disponibile in diretta e come registrazione archiviatacons sul sito web dell'azienda per almeno 14 giorni.
Revolution Medicines (Nasdaq: RVMD), una empresa de oncología en etapa clínica, anunciará sus resultados financieros para el tercer trimestre de 2024 el 6 de noviembre de 2024, después del cierre del mercado.
Una webcast presentada por la alta dirección seguirá a las 4:30 p.m. Hora del Este (1:30 p.m. Hora del Pacífico) para discutir los resultados y proporcionar una actualización corporativa. La webcast estará disponible en vivo y como repetición archivada en el sitio web de la empresa durante al menos 14 días.
Revolution Medicines (Nasdaq: RVMD), 임상 단계의 온콜로지 회사가 2024년 3분기 재무 결과를 2024년 11월 6일, 시장 마감 후 발표할 예정입니다.
선임 경영진이 진행하는 웹캐스트가 동부 표준시 기준 오후 4시 30분 (태평양 표준시 기준 오후 1시 30분) 이후 결과를 논의하고 기업 업데이트를 제공하기 위해 진행됩니다. 웹캐스트는 회사 웹사이트에서 14일 이상 실시간 및 아카이브 재생으로 제공될 것입니다.
Revolution Medicines (Nasdaq: RVMD), une entreprise d'oncologie en phase clinique, présentera ses résultats financiers pour le troisième trimestre de 2024 le 6 novembre 2024, après la fermeture du marché.
Un webinaire animé par la direction suivra à 16h30, heure de l'Est (13h30, heure du Pacifique), pour discuter des résultats et fournir une mise à jour de l'entreprise. Le webinaire sera disponible en direct et en rediffusion archivée sur le site Web de l'entreprise pendant au moins 14 jours.
Revolution Medicines (Nasdaq: RVMD), ein klinisches Onkologieunternehmen, wird am 6. November 2024 nach Marktschluss seine Finanzzahlen für das 3. Quartal 2024 bekannt geben.
Ein Webcast, der von der Geschäftsleitung geleitet wird, folgt um 16:30 Uhr Eastern Time (13:30 Uhr Pacific Time), um die Ergebnisse zu erörtern und ein Unternehmensupdate zu geben. Der Webcast wird live und als archivierte Wiederholung für mindestens 14 Tage auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations. Following the live webcast, a replay will be available on the company’s website for at least 14 days.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.
FAQ
When will Revolution Medicines report its Q3 2024 financial results?
What time is the Revolution Medicines Q3 2024 financial results webcast?
Where can I access the Revolution Medicines Q3 2024 financial results webcast?
How long will the replay of the Revolution Medicines Q3 2024 financial results webcast be available?
